MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Angiogenesis and VEGF in Cancer
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,459 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,459 works in the cohort · of 4,299,418page 23 of 30

Labels cover 0 of 1,459 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,459 of 1,459 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affaboutunlabeled
Antibody Characterization Report for Angiogenin
Riham Ayoubi, Donovan Worrall, Peter S. McPherson, Carl Laflamme
2023· article· en· Zenodo (CERN European Organization for Nuclear Research)· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
1
citations
affno abstractunlabeled
Anti-angiogenic treatment for breast cancer?
Johannes P. van Netten, Stephen A. Hoption Cann, Ian Thornton, Rory P. Finegan, Christopher A. Maxwell
2017· letter· en· Cancer Treatment Reviews· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
Antiangiogenic Gene Therapy of Cancer
Steve Gyorffy, Jack Gauldie, A. Keith Stewart, Xiao‐Yan Wen
2007· book-chapter· en· Humana Press eBooks· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
The Role of the Vessel Wall
Anthony K.C. Chan
2013· article· en· Methods in molecular biology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
A phase Ib study of combined angiogenesis blockade with REGN910 (SAR307746), a selective monoclonal antibody (MAb) against angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid tumor malignancies.
Lieve Adriaens, Kyriakos P. Papadopoulos, Donna M. Graham, Amita Patnaik, Albiruni R. Abdul Razak, Anthony W. Tolcher +5 more
2013· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
1
citations
affunlabeled
Preclinical Drug Development Must Consider the Impact on Metastasis
Patricia S. Steeg, Robin L. Anderson, Menashe Bar‐Eli, Ann F. Chambers, Suzanne A. Eccles, Kent W. Hunter +7 more
2009· article· en· Clinical Cancer Research· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
1
citations

How this was built: Screen · Findings · About